Last reviewed · How we verify
2% sodium chondroitin sulfate
2% sodium chondroitin sulfate is a Small molecule drug developed by Watson Pharmaceuticals. It is currently in Phase 2 development. Also known as: Uracyst.
At a glance
| Generic name | 2% sodium chondroitin sulfate |
|---|---|
| Also known as | Uracyst |
| Sponsor | Watson Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Ocular burning
- Pruritus
- Foreign body sensation in the eye
- Eyestrain
- Tearing
- Ocular hyperemia
- Headache
Key clinical trials
- Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PHASE4)
- A Study to Assess Efficacy of Supporting Properties and Safety of ARTNEO in Patients With Knee Osteoarthritis (NA)
- Alternative Prophylaxis in Female Recurrent Urinary Tract Infections (PHASE4)
- Mesoglycan for Acute Hemorrhoidal Disease (NA)
- Intravesical Glycosaminoglycan Instillation and Urinary Tract Infection in Acute Spinal Cord Injury (PHASE1, PHASE2)
- Effects of Creatine Supplementation as Compared to Glucosamine/Chondroitin Sulfate Supplementation in Addition to Exercise and Physical Therapy in the Management of Knee Osteoarthritis. (NA)
- Effects of Glucosamine and Chondroitin Sulfate Supplementation in Addition to Resistance Exercise Training and Manual Therapy in Patients With Knee Osteoarthritis (NA)
- Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2% sodium chondroitin sulfate CI brief — competitive landscape report
- 2% sodium chondroitin sulfate updates RSS · CI watch RSS
- Watson Pharmaceuticals portfolio CI
Frequently asked questions about 2% sodium chondroitin sulfate
What is 2% sodium chondroitin sulfate?
2% sodium chondroitin sulfate is a Small molecule drug developed by Watson Pharmaceuticals.
Who makes 2% sodium chondroitin sulfate?
2% sodium chondroitin sulfate is developed by Watson Pharmaceuticals (see full Watson Pharmaceuticals pipeline at /company/watson-pharmaceuticals).
Is 2% sodium chondroitin sulfate also known as anything else?
2% sodium chondroitin sulfate is also known as Uracyst.
What development phase is 2% sodium chondroitin sulfate in?
2% sodium chondroitin sulfate is in Phase 2.
What are the side effects of 2% sodium chondroitin sulfate?
Common side effects of 2% sodium chondroitin sulfate include Ocular burning, Pruritus, Foreign body sensation in the eye, Eyestrain, Tearing, Ocular hyperemia.
Related
- Manufacturer: Watson Pharmaceuticals — full pipeline
- Also known as: Uracyst
- Compare: 2% sodium chondroitin sulfate vs similar drugs
- Pricing: 2% sodium chondroitin sulfate cost, discount & access